Salemonline Journal

Progressive Familial Intrahepatic Cholestasis: Market Insights and Market Trend by DelveInsight

 Breaking News
  • No posts were found

Progressive Familial Intrahepatic Cholestasis: Market Insights and Market Trend by DelveInsight

February 26
21:52 2021
Progressive Familial Intrahepatic Cholestasis: Market Insights and Market Trend by DelveInsight

DelveInsight has launched a new report on Progressive Familial Intrahepatic Cholestasis Market

 

Progressive Familial Intrahepatic Cholestasis is a disorder that causes progressive liver disease, which typically leads to liver failure in which liver cells are unable to secrete a digestive fluid called bile. The buildup of bile in liver cells causes liver disease in affected individuals. The average age at onset is three months, although some patients do not develop jaundice until later, even as late as adolescence. PFIC can progress rapidly and cause cirrhosis during infancy or may progress relatively slowly with minimal scarring into adolescence. Few patients survive into the third decade of life without treatment.

 

The key players elaborated in the Progressive Familial Intrahepatic Cholestasis Market report includes Mirum Pharmaceuticals, Albiro etc

 

Download Free Report Sample- https://www.delveinsight.com/sample-request/progressive-familial-intrahepatic-cholestasis-pfic-market

 

There are mainly three types of PFIC which occur due to mutations in the genes, such as ATP8B1, ABCB11, and ABCB4, which result in development of PFIC1, PFIC2, and PFIC3 respectively. Mutations in these genes lead to a failure of proteins to function normally and thereby cause PFIC in many patients. PFIC usually appears in the first months of life in patients with PFIC1 resulting in characterized by recurrent episodes of jaundice, which become permanent later in the course of the disease. In case of PFIC2, the initial presentation and the evolution seem to become more severe, resulting into permanent jaundice from the first months of life and the rapid appearance of liver failure within the first years of life.

 

Progressive Familial Intrahepatic Cholestasis Market Key Companies

  • Mirum Pharmaceuticals
  • Albiro

 

Progressive Familial Intrahepatic Cholestasis Market Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Progressive Familial Intrahepatic Cholestasis Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

 

Browse Free Sample Reporthttps://www.delveinsight.com/sample-request/progressive-familial-intrahepatic-cholestasis-pfic-market

 

Progressive Familial Intrahepatic Cholestasis Market Insights

The market for the treatment of Progressive Familial Intrahepatic Cholestasis is likely to experience significant annual growth over the 2018–2030 study period, as major-market sales are expected to increase by 2030.  

 

Global Progressive Familial Intrahepatic Cholestasis Treatment Market

The market of PFIC holds a critical unmet need as there are no US FDA approved medications available to meet the demands of the patients. Overall, the global Progressive Familial Intrahepatic Cholestasis (PFIC) therapeutics market is further expected to increase via efficient research and development [2020–2030].

 

Progressive Familial Intrahepatic Cholestasis Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

 

Download Free Report Overview- https://www.delveinsight.com/report-store/progressive-familial-intrahepatic-cholestasis-pfic-market

 

Table of content

1. Key Insights

2. Executive Summary of Progressive Familial Intrahepatic Cholestasis (PFIC)

3. Competitive Intelligence Analysis for Progressive Familial Intrahepatic Cholestasis (PFIC)

4. Progressive Familial Intrahepatic Cholestasis (PFIC) : Market Overview at a Glance

5. Progressive Familial Intrahepatic Cholestasis (PFIC) : Disease Background and Overview

6. Patient Journey

7. Progressive Familial Intrahepatic Cholestasis (PFIC) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Progressive Familial Intrahepatic Cholestasis (PFIC) Treatment

11. Marketed Products

12. Emerging Therapies

13. Progressive Familial Intrahepatic Cholestasis (PFIC) : Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Progressive Familial Intrahepatic Cholestasis (PFIC)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. AboutDelveInsight

 

Enquire about Progressive Familial Intrahepatic Cholestasis Market https://www.delveinsight.com/report-store/progressive-familial-intrahepatic-cholestasis-pfic-market

About Us

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.

  

Contact Us:

Shruti Thakur

[email protected]

+91-9650213330

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles